Disorders of lipid metabolism statins reduce the levels of C-reactive protein

Disorders of lipid metabolism statins reduce the levels of C-reactive proteinDisorders of lipid metabolism statins reduce the levels of C-reactive protein Previously it was demonstrated that statins can reduce the concentration of C-reactive protein (CRP) in patients with normo - or hypercholesterolemia. However, it was not known, is there a similar effect with hypertriglyceridemia and normal/increased concentration of cholesterol low-density lipoprotein (LDL). Dr. Michele Mercuri and his colleagues at Merck Research Laboratories (Rahway, NJ) studied the effects of simvastatin in 130 patients with combined hyperlipidemia and 195 patients with hypertriglyceridemia. The results of these double-blind placebo-controlled studies published in the November issue of the American Journal of Cardiology. The source levels of LDL and cholesterol in high density lipoprotein (HDL cholesterol), but not triglycerides, weakly correlated with baseline CRP concentrations. In addition, body mass index and hungry (on empty stomach levels of insulin and glucose correlated with CRP values. In both groups the simvastatin was associated with a significant decrease in the concentration of CRP, compared with placebo (p<0.05). According to multivariate analysis, the only reliable predictors of the dynamics of CRP levels to 6 weeks intervention was assigned to an active treatment and the original numbers of the SLO. Simvastatin had no effect on concentrations of vascular cell adhesion molecules, serum amyloid a and interleukin-6 are also considered to be markers of cardiovascular risk. 'Thus, the anti-inflammatory effects of statins observed in patients with severe hypertriglyceridemia' make the withdrawal of American scientists. Source: Solvay Pharma.



Похожие статьи

Ваше имя
Ваша почта
Город, область
Рассылка комментариев





Ввести код: